# Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)

> **NCT01074047** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 488 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Conventional Care Regimen

## Key facts

- **NCT ID:** NCT01074047
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06-01
- **Primary completion:** 2014-01-22
- **Final completion:** 2016-07-25
- **Target enrollment:** 488 (ACTUAL)
- **Last updated:** 2017-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01074047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01074047, "Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01074047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*